SCHEMBL7696803

SCHEMBL7696803

O=C(NCC(=O)[C@H](Cc1ccccc1)NC(=O)c1cccc(NS(=O)(=O)c2ccc3ncccc3c2)c1)c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
PFKFB3 Q16875 1/20 0.44
LMNA P02545 2/20 0.43
PABPC1 P11940 1/20 0.43
HDAC1 Q13547 2/20 0.43
HSD17B1 P14061 1/20 0.42
HSD17B2 P37059 1/20 0.42
BCAT1 P54687 1/20 0.42
CCR1 P32246 1/20 0.42
NAMPT P43490 2/20 0.42
HTT P42858 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
KDM1A O60341 1/20 0.41
MAOA P21397 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7689353 0.94 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PFKFB3LMNAPABPC1
SCHEMBL7699311 0.91 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2PFKFB3LMNAPABPC1
SCHEMBL7695659 0.85 KDM1A (0.51) ALDH1A1PFKFB3MAPTMEN1KMT2A
SCHEMBL7695396 0.82 AKR1C3 (0.48) ALDH1A1SMN1; SMN2LMNAHDAC1HTT
SCHEMBL7695272 0.82 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2LMNAHDAC1MEN1
SCHEMBL7692550 0.80 AKR1C3 (0.51) ALDH1A1SMN1; SMN2PFKFB3LMNAMEN1
SCHEMBL7694179 0.79 AKR1C3 (0.48) ALDH1A1SMN1; SMN2LMNA
SCHEMBL7694334 0.78 ALDH1A1 (0.49) ALDH1A1PFKFB3MEN1KMT2AKDM1A
SCHEMBL7659849 0.77 AKR1C3 (0.47) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL6942392 0.76 AKR1C3 (0.48) ALDH1A1SMN1; SMN2HTTNPSR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6436925-B1 BETTER ABLE TO CROSS MEMBRANES; INHIBITORS OF CYSTEINE PROTEASES LIKE CALPAIN I AND II AND CATHEPSIN B AND L, CAN THUS BE USED TO CONTROL DISEASES ASSOCIATED WITH AN ELEVATED ACTIVITY OF CALPAIN ENZYMES OR CATHEPSIN ENZYMES ABBOTT LABORATORIES 2002-08-20 US disclosed